Pepinemab Clinical Trial Ongoing; Top-line Results Coming Later this Year
Vaccinex’s Phase 2 SIGNAL study, evaluating the investigational antibody pepinemab (VX15/2503) in Huntington’s disease patients with late prodromal and early disease, is ongoing and has tested pepinemab in all 265 patients enrolled in cohort B, the company announced. As of March 31, only 37 patients in this group…